KLRC1 and B-cell non-Hodgkin lymphoma: Anti-NKG2A mAb as a monotherapy did not increase the survival of mice in a B-cell lymphoma pre-clinical model [62] and this lack of efficacy as a single agent was also reflected in clinical trials (NCT02459301) [63] (NCT03088059) [64].